Revolutionizing Cancer Treatment: Calico Biosystems Leads the Way
June 26, 2024, 3:31 pm
Calico Biosystems, a Swiss medtech company, is making waves in the cancer treatment industry with its innovative approach to predicting drug efficacy in cancer patients. With a recent funding boost of CHF 150,000 from Venture Kick, the company is poised to revolutionize the way cancer treatments are developed and administered.
The current landscape of cancer therapeutics is bleak, with a staggering failure rate of over 95% and limited patient response to approved treatments. Calico Biosystems is tackling this challenge head-on by combining experimental and digital methods to evaluate treatment efficacy directly in patient tumors. This approach overcomes the limitations of current models, which often fail to capture the complexity of cancer biology.
By leveraging computational modeling, Calico Biosystems is able to predict the most effective therapeutic combinations for clinical use. This not only improves the efficacy of treatments but also makes them more affordable for patients. With the Precision Oncology market projected to reach over USD 250 billion by 2030, Calico Biosystems is well-positioned to capture a significant share of this lucrative industry.
The company's co-founders, CEO Marie-Agnès Doucey and CSO Riccardo Turrini, bring over 15 years of experience in systems immuno-oncology to the table. Their dedication to pushing the boundaries of cancer treatment has been recognized by Venture Kick, which has provided crucial funding to support Calico Biosystems' market entry, innovation, and business growth.
In a statement, Riccardo Turrini emphasized the impact of the funding, stating, "This exceptional program helped us get the right mindset, kicked us out of our comfort zone, and challenged our vision, pushing us to focus on what matters to achieve a successful business strategy." With this support, Calico Biosystems is poised to lead the way in revolutionizing cancer treatment and improving outcomes for patients worldwide.
The current landscape of cancer therapeutics is bleak, with a staggering failure rate of over 95% and limited patient response to approved treatments. Calico Biosystems is tackling this challenge head-on by combining experimental and digital methods to evaluate treatment efficacy directly in patient tumors. This approach overcomes the limitations of current models, which often fail to capture the complexity of cancer biology.
By leveraging computational modeling, Calico Biosystems is able to predict the most effective therapeutic combinations for clinical use. This not only improves the efficacy of treatments but also makes them more affordable for patients. With the Precision Oncology market projected to reach over USD 250 billion by 2030, Calico Biosystems is well-positioned to capture a significant share of this lucrative industry.
The company's co-founders, CEO Marie-Agnès Doucey and CSO Riccardo Turrini, bring over 15 years of experience in systems immuno-oncology to the table. Their dedication to pushing the boundaries of cancer treatment has been recognized by Venture Kick, which has provided crucial funding to support Calico Biosystems' market entry, innovation, and business growth.
In a statement, Riccardo Turrini emphasized the impact of the funding, stating, "This exceptional program helped us get the right mindset, kicked us out of our comfort zone, and challenged our vision, pushing us to focus on what matters to achieve a successful business strategy." With this support, Calico Biosystems is poised to lead the way in revolutionizing cancer treatment and improving outcomes for patients worldwide.